Navigation Links
TapImmune to Participate in Two Upcoming Investor and Industry Conferences
Date:3/22/2017

JACKSONVILLE, Fla., March 22, 2017 /PRNewswire/ -- TapImmune, Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics for the treatment of cancer and metastatic disease, today announced that it will participate in two upcoming Investor and Industry conferences.

Dr. Glynn Wilson, Chairman and CEO of TapImmune, will provide an overview of the company's business, clinical pipeline and partnering opportunities for its proprietary PolyStart technology platform during his presentation at the 5th Annual Cancer Biopartnering & Investment Forum hosted by Sachs Associates in New York, NY.  Additionally, Dr. Wilson will serve as a panelist during the conference's "Cancer Vaccines: Immuno-Priming and Tumor Antigens" panel discussion.

Continue Reading
TapImmune to Participate in the 5th Annual Cancer Biopartnering & Investment Forum hosted by Sachs Associates in New York, and the Oligonucleotide & Peptide Therapeutics Conference in Boston.
TapImmune to Participate in the 5th Annual Cancer Biopartnering & Investment Forum hosted by Sachs Associates in New York, and the Oligonucleotide & Peptide Therapeutics Conference in Boston.

Concurrently, Dr. John Bonfiglio, President and Chief Operating Officer of TapImmune, will provide an overview of the company's unique approach during a presentation titled "Synthesis, Purification and Formulation of a New T Cell Vaccine Using 5 Novel Proteins," during the S2 Oligonucleotide & Peptide Therapeutics Boston Conference in Boston, MA.

Event:Sachs' 5th Annual Cancer Biopartnering & Investment ForumDate: Tuesday, March 28, 2017Times: Company presentation: 10:35 am (Eastern Time)

Cancer vaccine panel discussion: 2:00 pm (Eastern Time)Location:The New York Academy of Sciences, New York, NY Event:S2 Oligonucleotide & Peptide Therapeutics Boston Conference Date: Wednesday, March 29, 2017Time: 1:30 pm (Eastern Time)Location:Royal Sonesta Boston, Cambridge, MA

The presentation of the Sachs' 5th Annual Cancer Biopartnering & Investment Forum will be webcast live and will remain available as an archive following the presentation.  To access the webcast, please visit the events page section of the TapImmune website at http://tapimmune.com/events/.

About TapImmune, Inc.
TapImmune, Inc. is a leader in the immunotherapy of woman's cancers advancing multiple Phase 2 and Phase 1b/2 clinical studies for the treatment of ovarian and breast cancer. The company's peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patient's killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The company's technologies may be used as stand-alone medications or in combination with current treatment modalities.

Please visit the company's website at www.tapimmune.com for more details. 

Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. The company assumes no obligation to update the forward-looking statements.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tapimmune-to-participate-in-two-upcoming-investor-and-industry-conferences-300427763.html


'/>"/>
SOURCE TapImmune, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. TapImmune Launches Phase 2 Ovarian Cancer Trial In Platinum-Sensitive Patients
2. TapImmune: Year End 2016 Update
3. TapImmune Announces Finalization of License Agreement With Mayo Clinic to Commercialize a HER2neu Vaccine
4. TapImmune to Present at the LD Micro Invitational in Los Angeles on June 7, 2016
5. TapImmune to Present at the 3rd Annual Growth Capital Expo in Las Vegas on May 4, 2016
6. TapImmune Announces Phase 2 Ovarian Cancer Trial Study with AstraZeneca/MedImmune and Sloan Kettering Cancer Institute
7. TapImmune Completes GMP Manufacturing and Release of TPIV 200 Vaccine
8. TapImmune Granted Fast Track Designation by U.S. Food & Drug Administration for its Lead Vaccine TPIV 200 in the Treatment of Ovarian Cancer
9. TapImmune to Present at Biotech Showcase 2016 in San Francisco on January 11, 2016
10. Immuno-Oncology Company, TapImmune Inc., Moves Corporate Headquarters to Jacksonville Florida
11. TapImmune to Present at Aegis Capital 2015 Growth Conference in Las Vegas on October 9, 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... , Oct. 2, 2017 Diplomat Pharmacy, ... 8th Day Software and Consulting, LLC , and named ... 8th Day Software, based in Tennessee , ... 8th Day expands EnvoyHealth,s service offerings for health care ... "In an interoperable ...
(Date:10/2/2017)... The Rebound mobile app is poised to become a vital ... prescription drug addiction. The app empowers users to develop an ... their dosage in a safe, controlled manner while maximizing well-being. ... 100,000 people to sign up will enjoy 3 months of ... ...
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. ... big data solutions, today announced that its MyDario product is expected to ... TV listings for when The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... As health ... medicine known as “patient engagement.” The patient is doing more than filling out a ... , “There is an increasing emphasis in health care and research on the ...
(Date:10/13/2017)... ... 2017 , ... PurhealthRX , a leading Health and Nutrition Company, is ... to full spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing ... easily incorporated into liquid products, while reducing costs to end users. , The team ...
(Date:10/13/2017)... ... 13, 2017 , ... Many families have long-term insurance that covers care for ... a waiver for care if the client has a cognitive impairment diagnosis. , ... care, is often waived, so the benefits from their insurance start immediately,” said Mechell ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history of ... Brink” is the creation of published author, William Nowers. Captain Nowers and his ... veteran, he spent thirty years in the Navy. Following his career as a ...
Breaking Medicine News(10 mins):